|
Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients < 50 years and >50 years. |
|
|
Research Funding - Agendia |
|
|
Speakers' Bureau - MJH Healthcare Holdings, LLC |
Research Funding - Agendia |
Travel, Accommodations, Expenses - Agendia |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Beam; Bluebird Bio; Conatus; Editas Medicine; Fate Therapeutics; Gilead Sciences; Immunogen; Immunomedics; Novocure; Pfizer; Viking Medical |
Honoraria - Agendia; AstraZeneca; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer |
Consulting or Advisory Role - Agendia; Genentech; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology |
Speakers' Bureau - Agendia; Genentech; Genomic Health; Lilly; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Genentech; Lilly; Novartis; Pfizer |
|
|
Leadership - SEngine Precision Medicine |
Stock and Other Ownership Interests - 3rdEyeBio; New Equilibrium Biosciences; Novilla; Sengine precision medicine |
Consulting or Advisory Role - Novartis; Puma Biotechnology; Sanofi; Seagen |
Speakers' Bureau - bioTheranostics; Seagen |
Research Funding - Agendia; Genentech/Roche (Inst); SignalOne Bio |
Travel, Accommodations, Expenses - Novartis |
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
No Relationships to Disclose |